EP4719365A1 — Combination therapy with a mtor inhibitor and a multi-tyrosine kinase inhibitor for treating soft tissue sarcoma
Assigned to Whitehawk Therapeutics Inc · Expires 2026-04-08 · 0y expired
What this patent protects
The present application, in certain aspects, pertains to methods and compositions for the treatment of a soft-tissue sarcoma (STS; such as spindle cell sarcoma, solitary fibrous tumor, or leiomyosarcoma), using a composition comprising nanoparticles comprising an mTOR inhibitor (…
USPTO Abstract
The present application, in certain aspects, pertains to methods and compositions for the treatment of a soft-tissue sarcoma (STS; such as spindle cell sarcoma, solitary fibrous tumor, or leiomyosarcoma), using a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, e.g, sirolimus or a derivative thereof) and an albumin in combination with a multi-tyrosine kinase inhibitor (such as pazopanib).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.